Compare Stocks: VSTM, NAMS, ZLAB, and CLDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$29.30 -3.7%	$37.90	$22.10 ▼ $45.14	$2.30B	0.9	2.25 million shs	3.95 million shs
NAMS NewAmsterdam Pharma	$21.26 -3.9%	$25.03	$20.91 ▼ $42.21	$2.65B	0.1	1.84 million shs	1.67 million shs
VSTM Verastem	$8.11 -1.9%	$7.37	$3.43 ▼ $10.82	$748.51M	0.39	2.37 million shs	3.05 million shs
ZLAB Zai Lab	$24.81 -2.0%	$24.90	$15.96 ▼ $33.65	$2.88B	0.73	849,930 shs	979,117 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-3.71%	-8.95%	-25.10%	-25.08%	+7.56%
NAMS NewAmsterdam Pharma	-3.93%	-12.00%	-17.05%	-39.71%	-35.30%
VSTM Verastem	-1.93%	+2.66%	+0.37%	+46.65%	-9.28%
ZLAB Zai Lab	-1.98%	-2.71%	-2.36%	+21.08%	-26.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$29.30 -3.7%	$37.90	$22.10 ▼ $45.14	$2.30B	0.9	2.25 million shs	3.95 million shs
NAMS NewAmsterdam Pharma	$21.26 -3.9%	$25.03	$20.91 ▼ $42.21	$2.65B	0.1	1.84 million shs	1.67 million shs
VSTM Verastem	$8.11 -1.9%	$7.37	$3.43 ▼ $10.82	$748.51M	0.39	2.37 million shs	3.05 million shs
ZLAB Zai Lab	$24.81 -2.0%	$24.90	$15.96 ▼ $33.65	$2.88B	0.73	849,930 shs	979,117 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-3.71%	-8.95%	-25.10%	-25.08%	+7.56%
NAMS NewAmsterdam Pharma	-3.93%	-12.00%	-17.05%	-39.71%	-35.30%
VSTM Verastem	-1.93%	+2.66%	+0.37%	+46.65%	-9.28%
ZLAB Zai Lab	-1.98%	-2.71%	-2.36%	+21.08%	-26.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.86	Moderate Buy	$61.92	111.34% Upside
NAMS NewAmsterdam Pharma	2.85	Moderate Buy	$49.00	130.48% Upside
VSTM Verastem	2.75	Moderate Buy	$13.83	70.57% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$37.25	50.14% Upside

Current Analyst Ratings Breakdown

Latest VSTM, NAMS, ZLAB, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	VSTM Verastem	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/6/2026	ZLAB Zai Lab	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
10/5/2026	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$50.00 ➝ $42.00
10/5/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
10/5/2026	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
10/2/2026	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$64.00
9/28/2026	VSTM Verastem	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/23/2026	CLDX Celldex Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$70.00 ➝ $88.00
9/23/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$50.00 ➝ $57.00
9/22/2026	CLDX Celldex Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$68.00
9/22/2026	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $64.00

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$158K	14,562.84	N/A	N/A	$7.93 per share	3.69
NAMS NewAmsterdam Pharma	$22.50M	112.95	N/A	N/A	$5.97 per share	3.56
VSTM Verastem	$30.91M	23.76	N/A	N/A	$0.74 per share	10.96
ZLAB Zai Lab	$460.16M	6.13	N/A	N/A	$6.39 per share	3.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
VSTM Verastem	-$209.47M	-$2.66	N/A	N/A	N/A	-231.59%	-467.49%	-94.54%	11/3/2026 (Estimated)
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	11/5/2026 (Estimated)

Latest VSTM, NAMS, ZLAB, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ZLAB Zai Lab	-$0.5642	N/A	N/A	N/A	$108.84 million	N/A
11/4/2026	Q3 2026	NAMS NewAmsterdam Pharma	-$0.50	N/A	N/A	N/A	$7.54 million	N/A
11/3/2026	Q3 2026	VSTM Verastem	-$0.44	N/A	N/A	N/A	$29.32 million	N/A
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/6/2026	Q2 2026	VSTM Verastem	-$0.4305	-$0.35	+$0.0805	-$0.35	$22.88 million	$40.08 million
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	11.82	11.82
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
VSTM Verastem	1.48	2.25	2.22
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
NAMS NewAmsterdam Pharma	89.89%
VSTM Verastem	88.37%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	5.20%
NAMS NewAmsterdam Pharma	12.74%
VSTM Verastem	1.94%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	198	78.53 million	74.45 million	Optionable
NAMS NewAmsterdam Pharma	100	119.54 million	104.31 million	Optionable
VSTM Verastem	102	90.56 million	88.81 million	Optionable
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

VSTM, NAMS, ZLAB, and CLDX Headlines

Recent News About These Companies

Zai Lab stock closed at USD 25.58 before ESMO data

October 7 at 10:45 PM | ad-hoc-news.deA

Critical Comparison: Zai Lab (NASDAQ:ZLAB) vs. Anixa Biosciences (NASDAQ:ANIX)

October 7 at 5:15 AM | americanbankingnews.com

Zai Lab stock faces a key ESMO test after Cantor target call

October 7 at 1:21 AM | ad-hoc-news.deA

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's Why

October 6 at 11:20 AM | marketbeat.com

Is Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?

October 4, 2026 | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Stock Price Down 4.6% - Here's Why

October 2, 2026 | marketbeat.com

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

September 29, 2026 | marketscreener.comM

Zai Lab (NASDAQ:ZLAB) Stock Jumps 3.8% - What's Next?

September 28, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Stock Rating Raised to "Hold" at Wall Street Zen

September 26, 2026 | marketbeat.com

Zai Lab Ltd (ZLAB)

September 24, 2026 | in.investing.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages

September 23, 2026 | marketbeat.com

Zai Lab Limited (ZLAB)

September 11, 2026 | finance.yahoo.com

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

August 26, 2026 | cnbc.com

Zai Lab: Revenue Growth And Zoci's Upside Optionality

August 19, 2026 | seekingalpha.com

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CFO Sells 619 Shares

August 14, 2026 | insidertrades.com

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

August 10, 2026 | finance.yahoo.com

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 6, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, NAMS, ZLAB, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$29.30 -1.13 (-3.71%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$29.42 +0.12 (+0.41%)

As of 08:27 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

NewAmsterdam Pharma NASDAQ:NAMS

$21.26 -0.87 (-3.93%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$21.38 +0.13 (+0.59%)

As of 08:53 AM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Verastem NASDAQ:VSTM

$8.11 -0.16 (-1.93%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$7.97 -0.14 (-1.71%)

As of 08:51 AM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Zai Lab NASDAQ:ZLAB

$24.81 -0.50 (-1.98%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$24.56 -0.25 (-1.00%)

As of 08:53 AM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VSTM, NAMS, ZLAB, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VSTM, NAMS, ZLAB, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VSTM, NAMS, ZLAB, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, NAMS, ZLAB, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

NewAmsterdam Pharma NASDAQ:NAMS

Verastem NASDAQ:VSTM

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VSTM, NAMS, ZLAB, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VSTM, NAMS, ZLAB, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VSTM, NAMS, ZLAB, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, NAMS, ZLAB, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

NewAmsterdam Pharma NASDAQ:NAMS

Verastem NASDAQ:VSTM

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools